KPF
MDNA

K2 Principal Fund’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

K2 Principal Fund’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,167
Closed -$60K – 392
2020
Q4 		$60K Sell
10,167
-148,678
-94% -$599K 0.01% 294
2020
Q3 		$857K Buy
+158,845
New +$639K 0.13% 161

Other funds holding MDNA

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

K2 Principal Fund's MDNA Position: Q1 2021 in Review

K2 Principal Fund sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q1 2021, closing a stake of 10,167 shares — an estimated $60K sold.

K2 Principal Fund first reported a position in MDNA in Q3 2020 and held it in 2 quarters. The position peaked at $857K in Q3 2020. 31 funds tracked by Wall St. Rank hold MDNA as of Q1 2021.

  • K2 Principal Fund reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q1 2021 after selling out during the quarter.
  • K2 Principal Fund sold 10,167 Medicenna Therapeutics Corp. Common Shares shares in Q1 2021, an estimated $60K.
  • K2 Principal Fund first reported a position in Medicenna Therapeutics Corp. Common Shares in Q3 2020 and held it in 2 quarters.
  • K2 Principal Fund's Medicenna Therapeutics Corp. Common Shares position peaked at $857K in Q3 2020.
  • 31 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q1 2021.

Based on K2 Principal Fund's 13F filing for Q1 2021, filed 14 May 2021.